Ofev Seen to Slow Lung Function Decline Across SSc-ILD Subgroups

Ofev Seen to Slow Lung Function Decline Across SSc-ILD Subgroups

310331

Ofev Seen to Slow Lung Function Decline Across SSc-ILD Subgroups

Ofev (nintedanib) effectively slowed lung function decline in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD) across patient groups based on autoantibody status and skin involvement severity, according to an analysis of the SENSCIS trial. These findings add to the trial’s top-line results, which showed that one year of treatment with Ofev was superior to a placebo at reducing the rate of ILD progression in SSc patients, and supported the therapy’s benefits…

You must be logged in to read/download the full post.